Meagan Whisenant

Meagan Whisenant

Auto-generated profile, based on publicly available information

Meagan Whisenant

Cizik School of Nursing, The University of Texas Health Science Center at Houston

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KMKathi H. Mooney
Kathi H. Mooney
SBSusan L. Beck
Susan L. Beck
BWBob Wong
Bob Wong
WDWilliam Dunson
William Dunson
DWDebra Wujcik
Debra Wujcik
GDGary Donaldson
Gary Donaldson
Technology‐aided remote interventions for poorly controlled symptoms may improve cancer symptom outcomes. In a randomized controlled trial, the efficacy of an automated symptom management system was tested to determine if it reduced chemotherapy‐related symptoms. Prospectively, 358 patients beginning chemotherapy were randomized to the Symptom Care at Home (SCH) intervention (n = 180) or enhanced usual care (UC) (n = 178). Participants called the automated monitoring system daily reporting severity of 11 symptoms. SCH participants received automated self‐management coaching and nurse practitioner (NP) telephone follow‐up for poorly controlled symptoms. NPs used a guideline‐based decision support system. Primary endpoints were symptom severity across all symptoms, and the number of severe, moderate, mild, and no symptom days. A secondary endpoint was individual symptom severity. Mixed effects linear modeling and negative binominal regressions were used to compare SCH with UC. SCH participants had significantly less symptom severity across all symptoms (P < 0.001). On average, the relative symptom burden reduction for SCH participants was 3.59 severity points (P < 0.001), roughly 43% of UC. With a very rapid treatment benefit, SCH participants had significant reductions in severe (67% less) and moderate (39% less) symptom days compared with UC (both P < 0.001). All individual symptoms, except diarrhea, were significantly lower for SCH participants (P < 0.05). Symptom Care at Home dramatically improved symptom outcomes. These results demonstrate that symptoms can be improved through automated home monitoring and follow‐up to intensify care for poorly controlled symptoms.

1 May 2019 in Medical Care
Verified
Journal Article
Closed access
KMKathi PhD Mooney
Kathi PhD Mooney
MWMeagan S. PhD Whisenant
Meagan S. PhD Whisenant
SBSusan L. PhD Beck
Susan L. PhD Beck
Introduction: There is growing recognition that systematically obtaining the patient’s perspective on their health experience, using patient-reported outcomes (PRO), can be used to improve patient care in real time. Few PRO systems are designed to monitor and provide symptom management support between visits. Patients are instructed to contact providers between visits with their concerns, but they rarely do, leaving patients to cope with symptoms alone at home. We developed and tested an automated system, Symptom Care at Home (SCH), to address this gap in tracking and responding to PRO data in-between clinic visits. The purpose of this paper is to describe SCH as an example of a comprehensive PRO system that addresses unmet need for symptom support outside the clinic. Methods for PRO Score Interpretation: SCH uses pragmatic, single-item measures for assessing symptoms, which are commonly used and readily interpretable for both patients and providers. We established alerting values for PRO symptom data, which was particularly important for conserving oncology providers’ time in responding to daily PRO data. Methods for Developing Recommendations for Acting on PRO Results: The SCH system provides automated, just-in-time self-management coaching tailored to the specific symptom pattern and severity levels reported in the daily call. In addition, the SCH system includes a provider decision support system for follow-up symptom assessment and intervention strategies. Discussion: SCH provides PRO monitoring, tailored automated self-management coaching, and alerts the oncology team of poorly controlled symptoms with a provider dashboard that includes evidence-based decision support for follow-up to improve individual patients’ symptom care. We particularly emphasize our process for PRO selection, rationale for determining alerting thresholds, and the design of the provider dashboard and decision support. Currently, we are in the process of updating the SCH system, developing both web-based and app versions in addition to interactive voice response phone access and integrating the SCH system in the electronic health record.

1 November 2017 in Oncology Nursing Forum
Verified
Journal Article
Closed access
PDF file
MWMeagan Whisenant
Meagan Whisenant
BWBob Wong
Bob Wong
SMSandra A. Mitchell
Sandra A. Mitchell
SBSusan L. Beck
Susan L. Beck
KMKathi Mooney
Kathi Mooney
To examine self-reported severity of fatigue and disturbed sleep experienced daily by women with breast cancer during multiple cycles of chemotherapy, exploring potential classes of women experiencing similar symptom trajectories. . In a secondary analysis, classes of women experiencing similar patterns of fatigue and disturbed sleep were identified. . Oncology clinics in the United States. . 166 women with breast cancer receiving chemotherapy. . Severity scores were self-reported daily using an automated system. Classes of fatigue and disturbed sleep severity were identified using latent growth mixture modeling. . Fatigue, disturbed sleep, age, stage of disease, education, employment, marital status, chemotherapy regimen, hours lying down, and missed work. . Three fatigue classes were identified. Patterns of symptom trajectories for fatigue and disturbed sleep were distinguished by baseline symptom severity. . Identification of women at risk for fatigue and disturbed sleep may allow clinicians to intensify symptom management.

1 December 2021 in Seminars in Oncology Nursing
Verified
Journal Article
Closed access
MWMeagan S. Whisenant
Meagan S. Whisenant
SSSamer A. Srour
Samer A. Srour
LWLoretta A. Williams
Loretta A. Williams
ISIshwariah Subbiah
Ishwariah Subbiah
DGDonna Griffin
Donna Griffin
XWXin Shelley Wang
Xin Shelley Wang

14 November 2018 in Cancer Nursing
Verified
Journal Article
Closed access
MWMeagan PhD Whisenant
Meagan PhD Whisenant
BWBob Wong
Bob Wong
SMSandra A. PhD Mitchell
Sandra A. PhD Mitchell
SBSusan L. PhD Beck
Susan L. PhD Beck
KMKathi PhD Mooney
Kathi PhD Mooney
Background: Women are at risk of mood disturbance during treatment for breast cancer. Objective: The aims of this study were to identify classes of women experiencing similar trajectories of depressed mood and anxiety while receiving chemotherapy for breast cancer and to determine associated antecedents and outcomes. The specific aims were to (1) determine the distinct trajectory classes associated with severity of depressed mood and anxiety reported by women undergoing cycles 2 and 3 of chemotherapy for breast cancer, (2) determine if class membership is associated with various antecedent variables, and (3) determine if class membership is associated with days of missed work and hours spent lying down. Methods: In a secondary analysis, classes were identified using Latent Growth Mixture Modeling. Antecedents and outcomes related to class membership were explored. Results: Participants (n = 166; mean age, 53 [SD, 10.8] years) were mostly white (91.46%); half had early-stage disease. Two trajectories of depressed mood and anxiety were identified. Receipt of doxorubicin was associated with the higher severity class for depressed mood (P < .01) and anxiety (P = .04). No college education (P = .03) or spending more hours lying down (P = .03) was associated with the higher severity class for anxiety. Conclusions: Distinct trajectories of mood disturbance are distinguished by baseline severity. Further study is needed to determine if biologic or genomic factors are associated with class membership. Implications for Practice: Identification of women at risk of mood disturbance may allow clinicians to intensify symptom management. Mood disturbance early in the treatment trajectory warrants management to improve outcomes.

1 February 2019 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
MWMeagan Whisenant
Meagan Whisenant
BWBob Wong
Bob Wong
SMSandra A. Mitchell
Sandra A. Mitchell
SBSusan L. Beck
Susan L. Beck
KMKathi Mooney
Kathi Mooney